Loading…
← CockpitCompetitor Analysis › WELL.TO WELL Health Technologies Corp.Open in the cockpit ↗

WELL Health Technologies Corp.WELL.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Medical/Nursing Services
Momentum weak 39
Mkt cap
$661M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$4.52M
20-day average traded
Fwd P/E
10.1×
forward earnings
ROIC−WACC
-3.6 pp
WACC 7.3%
Hurdle
-84 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · CADC$3.70
1D+1.4%
1W-0.8%
1M-13.9%
3M-16.3%
6M-8.9%
YTD-7.3%
1Y-6.1%
ATR %4.5%
52w lowhigh28.7% off high

What WELL Health Technologies does

Employees: 3,200

WELL Health Technologies at a glance

Size WELL Health Technologies (WELL.TO) is a Canada Health Care company (Medical/Nursing Services) with a market value of $661M, the 289th largest of 405 Canada companies the cockpit tracks. Shares closed at C$3.70 on 18 Nov 2026.

Performance Over six months the shares fell 8.9%, against -6.2% for the median peer and +1.1% for the Canada market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 29.1% over the last twelve months (peer median +5.2%); the operating margin is 6.3% (peer median 7.5%).

Valuation It trades at 10.1× forward earnings against a peer median of 19.8× (2nd cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -84 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.6 points below its cost of capital (7.3% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 97WELL.TO 89
Six months, rebased to 100: WELL Health Technologies against the median of its 20 peers (local-currency closes).

WELL Health Technologies financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$1.56BC$1.40BC$920MC$776MC$569M
Revenue growth—+52%+19%+36%—
Gross profitC$590MC$525MC$291MC$311MC$248M
EBITDAC$205MC$207MC$52.9MC$102MC$81.7M
Net income-C$129M-C$7.36MC$32.6MC$82,000C$1.37M
Free cash flowC$66.0MC$87.9M-C$10.6MC$37.2MC$65.7M
Capital expenditureC$40.7MC$27.9MC$16.2MC$25.4MC$6.62M
Total debtC$909MC$711MC$473MC$426MC$358M

Quarterly statements and history in the cockpit →

WELL Health Technologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%FLGTNEPHROPLUSGMRS1951195940DNATTALO301060THYROCARE4694127120REGAHCO688315ACLIDXJSLL9860GDRXWELL.TO6-month return →1-month return →
Up and to the right = strong over both horizons. WELL Health Technologies is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×NEPHROPLUSGMRS1951195940TTALOTHYROCARE4694SRTA688315IDXJSLLWELL.TORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. WELL Health Technologies is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%NEPHROPLUSGMRS1951195940TTALO301060THYROCAREREGAHCOJSLL9860WELL.TOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. WELL Health Technologies is the large dot.

WELL Health Technologies competitors and peer comparison

How WELL Health Technologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

WELL Health Technologies against its 20 peers (data as of 18 Nov 2026)
MeasureWELL.TOPeer medianRank in peer set
1-month return-13.9%+1.0%6th lowest of 21
6-month return-8.9%-6.2%10th lowest of 21
Distance from 52-week high-28.7%-35.4%10th highest of 21
Revenue growth (TTM)+29.1%+5.2%4th highest of 21
Operating margin6.3%7.5%9th lowest of 21
Forward P/E10.1×19.8×2nd cheapest of 16
Growth the price implies (Req g, 7 yrs)10.1%7.5%8th most demanding of 17
Growth delivered (Del g)+94.5%+9.5%highest of 17
Hurdle (Req g minus delivered)-84.5 pp-1.2 ppleast demanding of 17
ROIC minus cost of capital-3.6 pp-0.3 pp7th lowest of 20
EV / EBITDA9.2×8.0×7th most expensive of 15
Net debt / EBITDA3.4×1.6×4th most indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%

Questions

Which companies are WELL Health Technologies's closest peers?
The cockpit's peer set: Fulgent Genetics (FLGT), Nephrocare Health Services (NEPHROPLUS.NS), GMR Solutions (GMRS), Jinxin Fertility (1951.HK), HK inno.N (195940.KS), Ginkgo Bioworks (DNA), Terveystalo Oy (TTALO.HE), Shanghai Labway Clinical Laboratory (301060.SZ).
Is WELL Health Technologies expensive compared with its peers?
On forward p/e it trades at 10.1× against a peer median of 19.8×, 2nd cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -84 pp: the price already allows for a slowdown.
How has WELL Health Technologies stock performed?
Over six months to 18 Nov 2026 the shares returned -8.9% against -6.2% for the median peer; over one year -6.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.